Rodilla, A.M.; Tavolacci, S.; Cagan, J.; Shah, T.; Mittan, S.; Mack, P.C.; Hirsch, F.R. Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review. Vaccines2023, 11, 969.
Rodilla, A.M.; Tavolacci, S.; Cagan, J.; Shah, T.; Mittan, S.; Mack, P.C.; Hirsch, F.R. Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review. Vaccines 2023, 11, 969.
Rodilla, A.M.; Tavolacci, S.; Cagan, J.; Shah, T.; Mittan, S.; Mack, P.C.; Hirsch, F.R. Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review. Vaccines2023, 11, 969.
Rodilla, A.M.; Tavolacci, S.; Cagan, J.; Shah, T.; Mittan, S.; Mack, P.C.; Hirsch, F.R. Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review. Vaccines 2023, 11, 969.
Abstract
In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and mortality associated with it. Considering this increased risk, and in order to prevent symptoms and severe disease, patients with lung cancer have been prioritized for COVID-19 vaccinations, primary and booster doses. Despite this, the pivotal clinical trials did not include these patients, which leaves open questions regarding vaccine efficacy and humoral immune response. This review outlines the findings of recent investigations into the humoral responses of lung cancer patients to COVID-19 vaccination, particularly the primary doses and first boost.
Keywords
lung cancer; SARS-CoV-2 vaccine; immunogenicity
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.